GlassScriptPhysician profile
Brian Thomas Carr
NPI 1750885513
$849.85
in general payments reported to CMS, 2019-2025
12 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.25 · 2024: $139 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $189.47 | 2025 | Signia, Interstim |
| Myriad Genetic Laboratories, INC. | $169.03 | 2025 | Myrisk |
| Baxter Healthcare | $140.28 | 2025 | Starling System |
| Guard Medical INC. | $138.73 | 2024 | Npseal Large |
| Medical Device Business Services, INC. | $79.64 | 2025 | Monocryl |
| Thd America, INC. | $22.81 | 2025 | |
| Heron Therapeutics, INC. | $21.49 | 2025 | Zynrelef |
| Kerecis Limited | $21.12 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Innovation Technologies INC | $20.14 | 2025 | Irrisept |
| Pacira Pharmaceuticals Incorporated | $18.89 | 2025 | Exparel |
| Erbe USA INC | $16.00 | 2025 | Vio3 |
| Takeda Pharmaceuticals U.S.A., INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.